{'fraction_non_alphanumeric': 0.023957409050576754, 'fraction_numerical': 0.005323868677905945, 'mean_word_length': 5.5964912280701755, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effect of lymph-stimulating drugs on the clinical manifestations and parameters of lipid metabolism in patients with post-infarction cardiosclerosis and angina pectoris].

As many as 64 patients with coronary heart disease (CHD) were examined. They were divided into 3 groups: (1) control subjects; (2) patients on supplementary rheogluman and (3) those on supplementary haemodesum (neocompensan). Their status was assessed from the frequency and intensity of anginal attacks, the magnitude of changes in lipid metabolic parameters prior to and following the therapy. Rheogluman and haemodesum were ascertained to have a favourable effect on the course of CHD, rheogluman producing a more beneficial effect. Supplementation of rheogluman to the treatment of CHD resulted in better correction of lipid metabolic disturbances in postinfarction cardiosclerosis to a greater extent than in angina. The hypolipidemic effect of haemodesum was slightly weaker than that of rheogluman. Rheogluman contributes to better correction of lipid parameters mainly in Type IIb hyperlipidemia, whereas haemodesum is more effective in type IIa.